GBT-440. caymanchem.com; abgerufen am 8. Februar 2022.
doi.org
D. Oksenberg, K. Dufu, M.P. Patel et al.: GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease. In: British Journal of Hematology, Band 75, Nr. 1, 2016, S. 141–153, doi:10.1111/bjh.14214.
E. Vichinsky, C.C. Hoppe, K.I. Ataga et al.: A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. In: New England Journal of Medicine, Band 381, 2019, S. 509–519, doi:10.1056/NEJMoa1903212.
J. Howard, K.I. Ataga, R.C. Brown et al.: Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. In: The Lancet Haematology, Band 8, Nr. 5, 2021, S. E323–E333, doi:10.1016/S2352-3026(21)00059-4.
C.P. Minniti, J. Knight-Madden, M. Tonda, S. Gray, J. Lehrer-Graiwer, B.J. Biemond: The impact of voxelotor treatment on leg ulcers in patients with sickle cell disease. In: American Journal of Hematology, Band 96, Nr. 4, 2021, S. E126–E128, doi:10.1002/ajh.26101.
